Malignancies Clinical Trial
Official title:
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered PWT33597 Mesylate in Subjects With Advanced Malignancies
This is a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics, and clinical effects of orally administered PWT33597 mesylate in subjects with advanced malignancies.
This is a multicenter, open-label, non-randomized, dose-escalation study, to be conducted in 2 phases. The Dose Escalation Phase (up to 36 patients) will determine the MTD of PWT33597 mesylate and evaluate its safety and tolerability, PK, PD, and preliminary clinical effects; the subsequent Dose Confirmation Phase (up to 36 patients) will be a cohort expansion at or below the MTD of PWT33597 mesylate. Subjects will be treated with once-daily oral doses of PWT33597 in consecutive, 28-day cycles. Subjects will be evaluated regularly for safety. Subjects will return for a follow-up visit 28 days after completion of the last dose of study drug. Subjects who tolerate the drug and who do not experience progressive disease may continue to receive PWT33597 mesylate at the discretion of the principal investigator for up to 24 cycles ;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Completed |
NCT03236857 -
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
|
Phase 1 | |
Completed |
NCT03005782 -
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
|
Phase 1 | |
Not yet recruiting |
NCT05602103 -
Cancer Therapy-related Cardiac Dysfunction Occuring in Children Treated by Anticancer Drugs for Malignancies
|
||
Terminated |
NCT00329329 -
Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies
|
Phase 1 | |
Completed |
NCT00316511 -
Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma
|
Phase 1 | |
Withdrawn |
NCT05253105 -
A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies
|
Phase 1 | |
Completed |
NCT02521389 -
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143
|
Phase 1 | |
Completed |
NCT01404728 -
Longitudinal Evaluation Study of Vaginal Stenosis With and Without Pelvic Radiation Therapy
|
N/A | |
Active, not recruiting |
NCT03678883 -
9-ING-41 in Patients With Advanced Cancers
|
Phase 2 | |
Not yet recruiting |
NCT05929495 -
Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma
|
Phase 2 | |
Completed |
NCT02257476 -
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00320827 -
Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)
|
Phase 1 |